- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 1
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of January 1, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 1.
Number 5: Many pharma companies rang in the new year with increases to their drugs’ list prices.
Number 4: The FDA has released new draft guidance for industry on good practices for submitting abbreviated new drug applications to speed generic drug approvals.
Number 3: New data show that LG Chem’s proposed biosimilar etanercept matches the reference Enbrel in terms of safety and efficacy.
Number 2: Drug maker Protalix announced positive phase 2 clinical data for an orally administered anti-TNF therapy.
Number 1: Momenta and Mylan have announced that they will begin clinical trials of M710, a proposed biosimilar to Eylea.
Finally, this week, contributor Brian Lehman explains why the so-called Medicare Part D “donut hole” creates an unintentional barrier to biosimilars in the United States. Read Lehman’s article and more content from expert contributors at centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
